Profiting From Pain #1

TReVoices Is the Leading The World Wide Charge To STOP The Travesty Of 'Medically Transitioning' Gender Confused Kids! Support Us Today - Donate

Welcome To TReVoices Blog By, Scott Newgent. If you believe in what we are doing, consider helping us with a gift.

---

Research companies regularly provide the pharmaceutical industry with reports containing projected growth forecasts for specific markets. Forecasts are based on such factors as government regulation (more regulation means a less-friendly market), number of market competitors (e.g., companies offering similar drugs), and other “market drivers [and] market barriers.” According to the “Research and Markets” website:

Calm Rational Debate

Buy Now

"The market size of Gender Dysphoria is expected to increase at a significant CAGR annual growth rate] during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest market size...With the consideration [of] technical, scientific, socio-economic, and regulatory advances, it can be safely assumed that the market is destined to undergo a noticeable boost in the coming days [2020-2030]”

Research companies charge thousands for the full report, so I do not know the exact growth forecast for the United States. However, the report summary also contains the following as reasons to purchase the full report:

• Organize sales and marketing efforts by identifying the best opportunities for gender dysphoria in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan

• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors

• 
  

Relentless Focus To Stop The Medicalization Of Gender Confused Children! Help Us Continue The Fight & Donate Now.

We cannot infer much about gender-dysphoric youth from the above report. However, on a general level, it is safe to say that the pharmaceutical industry does not expect the painful and widespread condition of gender dysphoria to abate in the US or Europe anytime soon, resulting in industry benefits in the millions of dollars.

We also can reasonably assume that companies will aggressively market their products where they see “the best opportunities for gender dysphoria” in order to “get[ ] ahead of competitors.” Some pharmaceutical companies have already had legal action taken against them for such aggressive tactics in their marketing of testosterone products, a subject I will explore in a future installment.

Bigot Today Hero Tomorrow

Buy Now

Within the US economic system, such companies are incentivized toward profit and against non-invasive solutions to gender dysphoria, despite the fact that there are known harmful side effects to their products for adults. There are no longitudinal studies on the side effects of these treatments on minors, but we can safely assume that if the treatments are risky for a fully grown patient, it is also likely they carry risks for those who are not fully mature.

Gender Dysphoria - Market Insight, Epidemiology and Market Forecast - 2030. researchandmarkets.com. October 2020.

https://www.researchandmarkets.com/reports/5180470/gender-dysphoria-market-insight-epidemiology?utm_source=BW&utm_medium=PressRelease&utm_code=vtp3tz&utm_campaign=1462961+-+Gender+Dysphoria+Market+Insight%2c+Epidemiology+and+Market+Forecast%2c+2017-2030&utm_exec=chdo54prd. Accessed 29 May, 2021.

FUTURE ARTICLES:

Future parts will explore

1) pharma defense strategies against litigation;

2) the medical industry growth forecast;

3) how "sex" and "gender" are being taught in some high-profile medical schools;

4) how data is used to perpetuate the trans-activist narrative;

5) detransitioners;

6) and how media is shaping the trans debate through unchallenging reporting.